AgomAb Therapeutics (AGMB)
Develops organ-restricted ALK5 inhibitors for fibro-inflammatory diseases.
$13.60
At close+0.06 (+0.44%)
In millions of USD, except per-share figures · converted from EUR at the latest rate
| In millions | Q4 FY24Dec 2024 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|
| 14 | 18 | 19 | |
| Research & development | 12 | 15 | 16 |
| 2 | 3 | 4 | |
| General & administrative | 2 | 3 | 4 |
| Other expenses | 0 | 0 | −1 |
| Operating income | −14 | −18 | −19 |
| 0 | −3 | −1 | |
| Interest income | 1 | 0 | 1 |
| Interest expense | 0 | 0 | 0 |
| Other non-operating income | 0 | 3 | 1 |
| Income before tax | −14 | −21 | −20 |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | −14 | −21 | −20 |
| Net income | −14 | −21 | −20 |
| EPS, basic | −$0.38 | −$0.50 | −$0.42 |
| EPS, diluted | −$0.38 | −$0.50 | −$0.42 |
| Weighted average shares, basic | 36 | 42 | 49 |
| Weighted average shares, diluted | 36 | 42 | 49 |
| EBITDA | −14 | −21 | −20 |
| Depreciation & amortization | 0 | 0 | 0 |
| EBIT | −14 | −21 | −20 |